
Chris Johnson Foundation Inc.
@renalmedullary
The Chris CJ Johnson Foundation Inc is a 501 (c)3 non profit charity organization located in Sugar Land Texas. Organized to create RMC awareness.
ID: 3387617914
http://chrisjohnsonfoundation.org 22-07-2015 16:26:37
1,1K Tweet
215 Followers
341 Following

👇Unfortunately sunitinib, pazopanib and cabozantinib are ineffective against #RenalMedullaryCarcinoma and need to be taken off this chart as they will produce toxicity without benefit. More info here: rmcalliance.org/treatment-info… Laurence Albiges Kidney Cancer RMC Alliance Chris Johnson Foundation Inc.


Congratulations, Gabrielle. We are proud of you. Losing your Dad to RMC at the young age of 6 has created a roller coasterof emotions, but you remained strong and resilient. As One Foundation Dr. Kimryn Rathmell Kidney Cancer Pavlos Msaouel Katie Coleman instagram.com/reel/C7ebUvHOQ…

.National Cancer Institute-funded researchers are working to improve our understanding of how to treat tumors in the brain or spinal cord. These tumors may be benign or malignant, but even non-cancerous tumors may need urgent treatment. go.nih.gov/Vohhe2S #BTAM #BTSM

It was a pleasure to join the ASCO Board of Directors this morning. I enjoyed catching up with Drs. Lynn Schuchter Eric J. Small, MD, FASCO, Eric Winer Yale Cancer Center, and others. #ASCO24







Thank you Jeff Rathmell for an enlightening presentation on obesity and immunotherapy at #KCRS24! Obesity impacts cancer risk but might boost response to treatments. Exciting insights on how blocking PD-1 can enhance anti-tumor immunity. #KidneyCancer #ResearchRevolution



Kimryn Rathmell Dr. Kimryn Rathmell Sumanta K. Pal, MD, FASCO Katie Coleman Salvatore La Rosa Aly-Khan Lalani Christopher Wallis (he/him/his) Dr. Bishoy M. Faltas Tian Zhang, MD, MHS Samson W. Fine, MD 3/5 Heading steadily towards our benchmark goals to improve median survival to 2 years by 2025 & to 5 years by 2030: aacrjournals.org/cancerres/arti… Avoiding treatments made for clear cell #kidneycancer & introducing biology-driven salvage therapies such as EGFRi made a difference.


Kimryn Rathmell Dr. Kimryn Rathmell Sumanta K. Pal, MD, FASCO Katie Coleman Salvatore La Rosa Aly-Khan Lalani Christopher Wallis (he/him/his) Dr. Bishoy M. Faltas Tian Zhang, MD, MHS Samson W. Fine, MD Daniel Shapiro Omar Alhalabi, MD jc Shilpa Gupta Shilpa Surasi Gabriel Malouf Sangeeta Goswami, MD,PhD Cristian Coarfa Qing Zhang Michael Serzan, MD 4/5 We found that retroperitoneal lymph nodes are by far the most common metastasis site, while brain mets appear relatively rare. RMC in the absence of sickle hemoglobinopathy (RCCU-MP) is very rare (~7% of cases) and may be less aggressive than typical #RenalMedullaryCarcinoma.






